11/14
08:30 am
igc
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline
Low
Report
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline
11/6
08:30 am
igc
IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies
Medium
Report
IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies
10/17
08:30 am
igc
IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1
Low
Report
IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1
10/3
09:00 am
igc
IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge
Low
Report
IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge
9/18
08:00 am
igc
IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment
High
Report
IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment
9/4
08:00 am
igc
IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease
High
Report
IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease
8/26
07:00 pm
igc
IGC Announces Results of its 2024 Annual Stockholders Meeting
Low
Report
IGC Announces Results of its 2024 Annual Stockholders Meeting